Kidney and Ureter Procedures for Neoplasm with CC DRG Reimbursement

DRG 657 applies to inpatient kidney and ureter procedures performed for neoplasm when a Complication or Comorbidity is present; it defines the clinical scope as oncologic urologic surgeries with additional complexity that increases resource needs. This matters for inpatient reimbursement because Diagnosis-Related Group assignment by the Centers for Medicare & Medicaid Services drives payment weighting and reflects the higher expected hospital resource use for these cases.

DRG 657 Overview

DRG 657 covers inpatient admissions for kidney and ureter surgical procedures performed for neoplasm when a Complication or Comorbidity is present. This Diagnosis-Related Group groups cases by procedure and clinical complexity to determine Medicare payment relative to resource use. It is used by the Centers for Medicare & Medicaid Services to classify and reimburse hospitals for higher-acuity oncologic urologic surgeries. Accurate coding of the principal procedure and the presence of Complication or Comorbidity affects payment assignment.

Perioperative complication reduction trials examining enhanced recovery protocols and minimally invasive surgical approaches: studies in this area compare laparoscopic, robotic-assisted, and open nephrectomy or ureterectomy techniques and adjunct perioperative bundles (analgesia strategies, fluid management, thromboprophylaxis) to reduce intraoperative blood loss, transfusion requirements, and short-term complications. The patient population includes adults undergoing surgery for kidney or ureter neoplasms with comorbidities that place them in the CC (complication or comorbidity) category, such as renal insufficiency, cardiac disease, or obesity; trials often stratify by tumor stage and baseline renal function. This research is relevant to providers and payers because lower complication rates and shorter length of stay directly affect resource use, readmission risk, and episode costs for DRG 657 hospitalizations.
Comparative effectiveness studies of nephron-sparing versus radical procedures on oncologic and renal outcomes: these observational cohorts and randomized designs evaluate partial nephrectomy or segmental ureteral resection versus radical nephrectomy/nephroureterectomy in patients with localized renal or upper tract urothelial neoplasms, focusing on cancer control, preservation of glomerular filtration, and progression to chronic kidney disease. The target population includes patients with small or moderate-sized tumors where nephron preservation is feasible but complicated by baseline comorbid conditions that increase postoperative risk; studies may include subgroup analyses by baseline renal function and age. Findings inform surgical decision-making and payer coverage strategies because trade-offs between long-term dialysis risk, downstream costs of chronic kidney disease, and short-term surgical resource utilization are central to value assessment under this DRG.
Post-discharge outcomes and survivorship research assessing functional status, renal function trajectory, and readmission drivers: prospective cohort studies and quality-improvement trials follow patients after discharge to quantify rates and causes of 30- and 90-day readmission, declines in renal function, need for dialysis, and patient-reported functional recovery and quality of life. These studies focus on the high-risk subgroup within DRG 657 who have CC-level comorbidities (e.g., diabetes, pre-existing CKD, or cardiovascular disease) that predispose them to adverse post-acute events, and they evaluate interventions such as targeted discharge planning, early nephrology follow-up, or transitional care models. Results are directly relevant to hospitals and payers aiming to reduce costly readmissions, optimize post-acute resource allocation, and improve long-term outcomes that influence total episode cost and patient-centered care metrics.

Perioperative complication reduction trials examining enhanced recovery protocols and minimally invasive surgical approaches: studies in this area compare laparoscopic, robotic-assisted, and open nephrectomy or ureterectomy techniques and adjunct perioperative bundles (analgesia strategies, fluid management, thromboprophylaxis) to reduce intraoperative blood loss, transfusion requirements, and short-term complications. The patient population includes adults undergoing surgery for kidney or ureter neoplasms with comorbidities that place them in the CC (complication or comorbidity) category, such as renal insufficiency, cardiac disease, or obesity; trials often stratify by tumor stage and baseline renal function. This research is relevant to providers and payers because lower complication rates and shorter length of stay directly affect resource use, readmission risk, and episode costs for DRG 657 hospitalizations.
Comparative effectiveness studies of nephron-sparing versus radical procedures on oncologic and renal outcomes: these observational cohorts and randomized designs evaluate partial nephrectomy or segmental ureteral resection versus radical nephrectomy/nephroureterectomy in patients with localized renal or upper tract urothelial neoplasms, focusing on cancer control, preservation of glomerular filtration, and progression to chronic kidney disease. The target population includes patients with small or moderate-sized tumors where nephron preservation is feasible but complicated by baseline comorbid conditions that increase postoperative risk; studies may include subgroup analyses by baseline renal function and age. Findings inform surgical decision-making and payer coverage strategies because trade-offs between long-term dialysis risk, downstream costs of chronic kidney disease, and short-term surgical resource utilization are central to value assessment under this DRG.
Post-discharge outcomes and survivorship research assessing functional status, renal function trajectory, and readmission drivers: prospective cohort studies and quality-improvement trials follow patients after discharge to quantify rates and causes of 30- and 90-day readmission, declines in renal function, need for dialysis, and patient-reported functional recovery and quality of life. These studies focus on the high-risk subgroup within DRG 657 who have CC-level comorbidities (e.g., diabetes, pre-existing CKD, or cardiovascular disease) that predispose them to adverse post-acute events, and they evaluate interventions such as targeted discharge planning, early nephrology follow-up, or transitional care models. Results are directly relevant to hospitals and payers aiming to reduce costly readmissions, optimize post-acute resource allocation, and improve long-term outcomes that influence total episode cost and patient-centered care metrics.

OpenPayer

Summary & Overview

Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

DRG 657 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes